Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR2 C383R FGFR2 N550D FGFR2 N550K FGFR2 V565L |
Therapy | Erdafitinib |
Indication/Tumor Type | cholangiocarcinoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 C383R FGFR2 N550D FGFR2 N550K FGFR2 V565L | cholangiocarcinoma | predicted - resistant | Erdafitinib | Case Reports/Case Series | Actionable | In a retrospective analysis, a cholangiocarcinoma patient harboring FGFR2 C383R progressed on treatment with Balversa (erdafitinib) and was found to have acquired FGFR2 N550K and V565L via cell-free DNA, and FGFR2 N550D via cell-free DNA and tissue biopsy (PMID: 39706336; NCT01703481). | 39706336 |
PubMed Id | Reference Title | Details |
---|---|---|
(39706336) | A Model for Decoding Resistance in Precision Oncology: Acquired Resistance to FGFR inhibitors in Cholangiocarcinoma. | Full reference... |